{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:51:47Z","timestamp":1789602707376,"version":"build-2803163510"},"update-to":[{"DOI":"10.1371\/journal.ppat.1011856","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000}}],"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2022YFC2305800"],"award-info":[{"award-number":["2022YFC2305800"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2022YFC2305800"],"award-info":[{"award-number":["2022YFC2305800"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2022YFC2305800"],"award-info":[{"award-number":["2022YFC2305800"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32200765"],"award-info":[{"award-number":["32200765"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>The rapid emergence of SARS-CoV-2 variants of concern (VOCs) calls for efforts to study broadly neutralizing antibodies elicited by infection or vaccination so as to inform the development of vaccines and antibody therapeutics with broad protection. Here, we identified two convalescents of breakthrough infection with relatively high neutralizing titers against all tested viruses. Among 50 spike-specific monoclonal antibodies (mAbs) cloned from their B cells, the top 6 neutralizing mAbs (KXD01-06) belong to previously defined IGHV3-53\/3-66 public antibodies. Although most antibodies in this class are dramatically escaped by VOCs, KXD01-06 all exhibit broad neutralizing capacity, particularly KXD01-03, which neutralize SARS-CoV-2 from prototype to the emerging EG.5.1 and FL.1.5.1. Deep mutational scanning reveals that KXD01-06 can be escaped by current and prospective variants with mutations on D420, Y421, L455, F456, N460, A475 and N487. Genetic and functional analysis further indicates that the extent of somatic hypermutation is critical for the breadth of KXD01-06 and other IGHV3-53\/3-66 public antibodies. Overall, the prevalence of broadly neutralizing IGHV3-53\/3-66 public antibodies in these two convalescents provides rationale for novel vaccines based on this class of antibodies. Meanwhile, KXD01-06 can be developed as candidates of therapeutics against SARS-CoV-2 through further affinity maturation.<\/jats:p>","DOI":"10.1371\/journal.ppat.1011856","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T13:32:50Z","timestamp":1701696770000},"page":"e1011856","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":35,"title":["Breakthrough infection elicits hypermutated IGHV3-53\/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including the emerging EG.5 lineages"],"prefix":"10.1371","volume":"19","author":[{"given":"Ling","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuowei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7399-3229","authenticated-orcid":true,"given":"Teng","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"issue":"3","key":"ppat.1011856.ref001","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40259-022-00529-7","article-title":"Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.","volume":"36","author":"WR Strohl","year":"2022","journal-title":"BioDrugs"},{"issue":"7902","key":"ppat.1011856.ref002","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa","volume":"603","author":"R Viana","year":"2022","journal-title":"Nature"},{"key":"ppat.1011856.ref003","first-page":"e939580","article-title":"Editorial: The XBB.1.5 (\u2019Kraken\u2019) Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.","volume":"29","author":"DV Parums","year":"2023","journal-title":"Med Sci Monit"},{"issue":"4","key":"ppat.1011856.ref004","doi-asserted-by":"crossref","first-page":"100991","DOI":"10.1016\/j.xcrm.2023.100991","article-title":"An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB","volume":"4","author":"Q He","year":"2023","journal-title":"Cell Rep Med"},{"issue":"2","key":"ppat.1011856.ref005","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","article-title":"Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster","volume":"29","author":"C Kurhade","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"ppat.1011856.ref006","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Q Wang","year":"2023","journal-title":"Cell"},{"issue":"7","key":"ppat.1011856.ref007","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1056\/NEJMc2214314","article-title":"Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1","volume":"388","author":"J Miller","year":"2023","journal-title":"N Engl J Med"},{"issue":"7948","key":"ppat.1011856.ref008","first-page":"521","article-title":"Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution","volume":"614","author":"Y Cao","year":"2023","journal-title":"Nature"},{"issue":"10","key":"ppat.1011856.ref009","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/S1473-3099(23)00555-8","article-title":"Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6","volume":"23","author":"Q Wang","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"ppat.1011856.ref010","doi-asserted-by":"crossref","first-page":"2270069","DOI":"10.1080\/22221751.2023.2270069","article-title":"Immune Evasion and Membrane Fusion of SARS-CoV-2 XBB Subvariants EG.5.1 and XBB.2.3","author":"JN Faraone","year":"2023","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"ppat.1011856.ref011","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/imr.13084","article-title":"Protective neutralizing epitopes in SARS-CoV-2","volume":"310","author":"H Liu","year":"2022","journal-title":"Immunol Rev"},{"key":"ppat.1011856.ref012","doi-asserted-by":"crossref","first-page":"101332","DOI":"10.1016\/j.coviro.2023.101332","article-title":"Broadly neutralizing antibodies against COVID-19.","volume":"61","author":"D Zhou","year":"2023","journal-title":"Curr Opin Virol"},{"issue":"6","key":"ppat.1011856.ref013","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.immuni.2022.03.019","article-title":"A large-scale systematic survey reveals recurring molecular features of public antibody responses to SARS-CoV-2","volume":"55","author":"Y Wang","year":"2022","journal-title":"Immunity"},{"issue":"7819","key":"ppat.1011856.ref014","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"R Shi","year":"2020","journal-title":"Nature"},{"issue":"7819","key":"ppat.1011856.ref015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"B Ju","year":"2020","journal-title":"Nature"},{"issue":"6556","key":"ppat.1011856.ref016","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.abh1139","article-title":"Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants","volume":"373","author":"M Yuan","year":"2021","journal-title":"Science"},{"issue":"7857","key":"ppat.1011856.ref017","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"P Wang","year":"2021","journal-title":"Nature"},{"issue":"4","key":"ppat.1011856.ref018","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"RE Chen","year":"2021","journal-title":"Nat Med"},{"issue":"6","key":"ppat.1011856.ref019","doi-asserted-by":"crossref","first-page":"112532","DOI":"10.1016\/j.celrep.2023.112532","article-title":"Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination","volume":"42","author":"B Ju","year":"2023","journal-title":"Cell Rep"},{"key":"ppat.1011856.ref020","doi-asserted-by":"crossref","first-page":"1178355","DOI":"10.3389\/fimmu.2023.1178355","article-title":"The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11.","volume":"14","author":"WD Tolbert","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"ppat.1011856.ref021","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.chom.2021.12.010","article-title":"Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers","volume":"30","author":"K Vanshylla","year":"2022","journal-title":"Cell Host Microbe"},{"issue":"11","key":"ppat.1011856.ref022","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","article-title":"Antibody evasion by the P.1 strain of SARS-CoV-2","volume":"184","author":"W Dejnirattisai","year":"2021","journal-title":"Cell"},{"issue":"4","key":"ppat.1011856.ref023","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41590-023-01449-6","article-title":"Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants","volume":"24","author":"B Ju","year":"2023","journal-title":"Nat Immunol"},{"issue":"1","key":"ppat.1011856.ref024","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41421-023-00569-5","article-title":"Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China.","volume":"9","author":"X Wang","year":"2023","journal-title":"Cell Discov"},{"issue":"1","key":"ppat.1011856.ref025","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chom.2020.11.007","article-title":"Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition","volume":"29","author":"AJ Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"7898","key":"ppat.1011856.ref026","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Y Cao","year":"2022","journal-title":"Nature"},{"issue":"1","key":"ppat.1011856.ref027","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1038\/s41467-021-24123-7","article-title":"Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain","volume":"12","author":"TJC Tan","year":"2021","journal-title":"Nat Commun"},{"key":"ppat.1011856.ref028","article-title":"Structural basis of Omicron neutralization by affinity-matured public antibodies.","author":"J. Daniel","year":"2022","journal-title":"bioRxiv"},{"issue":"3","key":"ppat.1011856.ref029","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41577-022-00753-w","article-title":"Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies","volume":"23","author":"BF Haynes","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"6280","key":"ppat.1011856.ref030","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1126\/science.aad9195","article-title":"HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen","volume":"351","author":"JG Jardine","year":"2016","journal-title":"Science"},{"issue":"3","key":"ppat.1011856.ref031","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.bbrc.2009.09.029","article-title":"Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens","volume":"390","author":"X Xiao","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"6133","key":"ppat.1011856.ref032","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"J Jardine","year":"2013","journal-title":"Science"},{"issue":"32","key":"ppat.1011856.ref033","doi-asserted-by":"crossref","first-page":"8614","DOI":"10.1073\/pnas.1709203114","article-title":"Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies","volume":"114","author":"JK Hwang","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"ppat.1011856.ref034","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.chom.2018.04.018","article-title":"Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development.","volume":"23","author":"K Wiehe","year":"2018","journal-title":"Cell Host Microbe"},{"issue":"1","key":"ppat.1011856.ref035","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/22221751.2021.1925594","article-title":"Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients","volume":"10","author":"Q Yan","year":"2021","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"ppat.1011856.ref036","doi-asserted-by":"crossref","first-page":"109771","DOI":"10.1016\/j.celrep.2021.109771","article-title":"Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses","volume":"37","author":"BB Banach","year":"2021","journal-title":"Cell Rep"},{"issue":"1","key":"ppat.1011856.ref037","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1080\/22221751.2022.2063074","article-title":"The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53\/3-66 antibodies in binding to SARS-CoV-2","volume":"11","author":"X Tian","year":"2022","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"ppat.1011856.ref038","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1038\/s41467-020-19231-9","article-title":"Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.","volume":"11","author":"NK Hurlburt","year":"2020","journal-title":"Nat Commun"},{"issue":"6566","key":"ppat.1011856.ref039","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1126\/science.abh2315","article-title":"Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study","volume":"374","author":"KM Hastie","year":"2021","journal-title":"Science"},{"issue":"7839","key":"ppat.1011856.ref040","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"CO Barnes","year":"2020","journal-title":"Nature"},{"issue":"1","key":"ppat.1011856.ref041","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41421-022-00449-4","article-title":"Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages","volume":"8","author":"X Li","year":"2022","journal-title":"Cell Discov"},{"issue":"74","key":"ppat.1011856.ref042","doi-asserted-by":"crossref","first-page":"eabo3425","DOI":"10.1126\/sciimmunol.abo3425","article-title":"Antibodies induced by an ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1.","volume":"7","author":"IW Windsor","year":"2022","journal-title":"Sci Immunol"},{"issue":"1","key":"ppat.1011856.ref043","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12929-023-00955-x","article-title":"Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2","volume":"30","author":"HL Chiang","year":"2023","journal-title":"J Biomed Sci"},{"issue":"1\u20132","key":"ppat.1011856.ref044","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","article-title":"Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning","volume":"329","author":"T Tiller","year":"2008","journal-title":"J Immunol Methods"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1011856","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1011856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T14:04:36Z","timestamp":1702562676000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1011856"}},"subtitle":[],"editor":[{"given":"Jesse D.","family":"Bloom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1011856","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,4]]}}}